Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07638566 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Study acronym: emlight
StatusNot Yet Recruiting
PhasePhase 2/3
Sponsorargenx
Started2026-09
View on ClinicalTrials.gov ↗
Argenx
56 trials monitored
See 2 trials at risk
The main purpose of the study is to determine the correct dose of empasiprubart in adolescent participants. It also aims to evaluate if empasiprubart may work and how safe it is for the use in children living with CIDP. The study consists of an open label treatment phase where participants will receive empasiprubart for up to 27 months approximately. After the final dose of empasiprubart, participants will enter a safety follow-up period for up to 14 months approximately. The overall study duration for each participant is up to 43 months. More information can be found here: clinicaltrials.argenx.com/emlight
Trial Details
NCT Number NCT07638566
Lead Sponsor argenx
Conditions Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment 6 participants
Start Date 2026-09
Primary Completion 2028-04 (estimated)
Study Completion 2031-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-10